PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS
The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC)..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 01. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
CONVERSO ANTONELLA [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-01, Last update posted on www.tib.eu: 2023-12-04, Last updated: 2023-12-08 |
|---|
| Patentnummer: |
CA3122571 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA011884444 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA011884444 | ||
| 003 | DE-627 | ||
| 005 | 20231208115006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210729s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA011884444 | ||
| 035 | |a (EPA)CA3122571 | ||
| 035 | |a (EPA)69411500 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a CONVERSO ANTONELLA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-01, Last update posted on www.tib.eu: 2023-12-04, Last updated: 2023-12-08 | ||
| 520 | |a The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC). | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a EL MARROUNI ABDELLATIF |4 aut | |
| 700 | 0 | |a FORSTER ASHLEY |4 aut | |
| 700 | 0 | |a FRIE JESSICA L |4 aut | |
| 700 | 0 | |a HUNTER DAVID N |4 aut | |
| 700 | 0 | |a KUDUK SCOTT D |4 aut | |
| 700 | 0 | |a MITCHELL HELEN J |4 aut | |
| 700 | 0 | |a NANTERMET PHILIPPE |4 aut | |
| 700 | 0 | |a SHA DEYOU |4 aut | |
| 700 | 0 | |a SHIPE WILLIAM DANIEL |4 aut | |
| 700 | 0 | |a WANG CHENG |4 aut | |
| 700 | 0 | |a WANG DEPING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 01. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/69411500/publication/CA3122571A1?q=CA3122571 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 01 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 08 | ||